Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's troponin test for Architect systems:

This article was originally published in Clinica

Executive Summary

Abbott Laboratories has received US FDA 510(k) clearance to run a test for the cardiac marker troponin I on its Architect line of immunoassay and immunochemistry analysers, the i2000SR and ci8200, respectively. The test marks the second assay in Abbott's acute cardiac panel for the Architect platform, says the Abbott Park, Illinois firm, which is developing additional cardiac assays. It is already available in major markets outside the US. The company added that based on the American College of Cardiology's new criteria for diagnosing heart attack, troponin has become the gold standard in diagnostic testing.

You may also be interested in...



Indian Telemedicine Prospects Boosted By Long-Awaited Guidelines

Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.

COVID-19 Vaccines Are Coming Soon, But Therapeutics Needed Now

Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.

Pfizer Holds Number One Spot And Takeda Breaks The Top 10

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel